Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Revelando lo invisible en España: Cómo la tecnología UV-C está impactando al mercado europeo

Puntos críticos: La pandemia validó la tecnología UV-C para el mundo médico, y ahora se están encontrando usos en otras industrias. El mercado español tiene varios sectores donde los rayos ultravioletas tipo C puedes ser útiles. El ecosistema de tecnologías sanitarias será critico para la salud de gente en nuestros ambientes públicos. El último año…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Revelando lo invisible en España: Cómo la tecnología UV-C está impactando al mercado europeo

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite
  • La pandemia validó la tecnología UV-C para el mundo médico, y ahora se están encontrando usos en otras industrias.
  • El mercado español tiene varios sectores donde los rayos ultravioletas tipo C puedes ser útiles.
  • El ecosistema de tecnologías sanitarias será critico para la salud de gente en nuestros ambientes públicos.

El último año y medio de disrupciones sanitarias ha revelado la importancia de mejores prácticas para mantener la salud de la gente en lugares públicos y de alto tráfico. En el primer episodio hispanohablante de Making the Invisible, Visible, un podcast de Intellego Technologies exploramos los beneficios de UV-C en este contexto. Vamos a explorar los casos de uso para rayos ultravioletas tipo C en las tecnologías biomédicas, pero no solo explorando como funciona la tecnología; también daremos puntos de vista en como maximizar esta tecnología en un ecosistema de soluciones innovadoras.

Nuestras invitadas, Patricia Pregel y Verónica Vidal, explican cómo esta tecnología ha avanzada en años recientes, y porque en la región europea, específicamente en España, se puede encontrar usos en varias industrias. Darémos respuestas a preguntas importantes, como…

  1. ¿Cómo funciona como una solución biomédica, y cómo se compara a otros rayos ultravioletas?
  2. ¿Cómo funcionan entro del ecosistema de tecnologías de saneamiento? ¿Qué reemplazan y qué complementan?
  3. ¿En cuales sectores españoles hay la mayoría de la oportunidades para usar el ecosistema de productos UV-C, y por qué?

Más información sobre nuestras invitadas:

  • Patricia Pregel es la directora de ventas de Intellego Technologies para el sur de Europa, LATAM y África.
  • Verónica Vidal está a cargo de Directora de Biodosimetría e Innovación para Fotoglass, una compañía creando aplicaciones ópticas para el sector industrial y biomédico, validando a la eficacia de tecnología crítica a estos sectores.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512